Michael Varenhorst, MD
Retina Specialist · Wichita, KSNPI 1730180886
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $6,800 of the $10,461 with a category attached, or 65.0%. US Retina LLC accounts for 65.0% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2022 at $2,804 and has fallen 67.4% since, to $913 in 2025.
Across 158 payments — averaging $66.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$7K
- Genentech USA, Inc.$763
- AbbVie$723
- Apellis Pharmaceuticals, Inc.$477
- ANI Pharmaceuticals, Inc.$359
- Regeneron Healthcare Solutions, Inc.$267
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,66135%
- Ownership interest$6,80065%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 5 | $6,800 |
| Genentech USA, Inc. | 33 | $763 |
| AbbVie(2 entities) | 33 | $723 |
| Apellis Pharmaceuticals, Inc. | 9 | $477 |
| ANI Pharmaceuticals, Inc. | 10 | $359 |
| Regeneron Healthcare Solutions, Inc. | 11 | $267 |
| Alimera Sciences, Inc. | 9 | $176 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $114 |
| Novartis | 6 | $110 |
| Eyepoint US, Inc. | 5 | $100 |
| Sandoz | 3 | $99 |
| Amgen(2 entities) | 5 | $88 |
| Bausch & Lomb Americas Inc. | 5 | $86 |
| Astellas Pharma US Inc | 4 | $77 |
| Mallinckrodt Enterprises LLC | 4 | $61 |
| Coherus Oncology, Inc. | 2 | $53 |
| Mallinckrodt Hospital Products Inc. | 2 | $33 |
| Biogen | 1 | $25 |
| Genentech, Inc. | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $19 |
| Topcon Healthcare, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Syfovre$258
- PURIFIED CORTROPHIN GEL$149
- OZURDEX$145
- Lucentis$123
How this compares
Too few retina specialist providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 139 | $3,895 |
| Latanoprost | 158 | $1,500 |
| MoxifloxacinMoxifloxacin Hcl | 45 | $1,414 |
| Difluprednate | 11 | $1,283 |
| Timolol Maleate | 34 | $1,164 |
| Ofloxacin | 92 | $1,095 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 73 | $990 |
| Ketorolac Tromethamine | 47 | $912 |
| Brimonidine Tartrate | 55 | $398 |
| Dorzolamide Hcl | 11 | $231 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Wichita
- Paul WeishaarWichita$17K
- Kumar DallaWichita$14K
- David ChackoWichita$8K
- Brooke NesmithWichita$6K
- Alan HromasWichita$3K
- Thomas WoltjerWichita$2K
- Charles BeckWichita$298
- Javed SayedLeawood$8K
- Mary ChampionPrairie Village$3K
- Radwan AjlanKansas City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.